2025

“Bitcoin’s Battle: Trump’s Executive Order for Crypto Stockpile Fails to Boost Struggling Price”

marketnews04 mins

Bitcoin Struggles Amidst Uncertainty Following Trump’s Executive Order Bitcoin and the broader crypto market have faced uncertainty following U.S. President Donald Trump’s executive order, which aimed to explore the creation of a national digital asset stockpile. Despite the significant implications for the cryptocurrency industry, Bitcoin has struggled to maintain upward momentum, with its price rejecting…

Read More

Tornado Cash Co-Founder Speaks Out: A Fight for Every Developer as DOJ Threatens 45-Year Prison Sentence

ilikefinance05 mins

The prosecution of Tornado Cash co-founder Roman Storm An assault on freedom and innovation Last week, Storm voiced his thoughts on X The prosecution of Tornado Cash co-founder Roman Storm is an egregious assault on freedom, innovation, and the very foundation of individual rights. It sets a dangerous precedent for the cryptocurrency community and threatens…

Read More

“Get Ready for a Vibrant Deal Activity: A Preview of Oxford Lane Capital’s Q2 FY25”

marketinsights02 mins

2025 Faces 2 Key Macro Scenarios Real-time Inflation Data and Industry Forecasts 2025 is shaping up to be a year of pivotal moments, with the global economy facing two key macro scenarios. Real-time inflation data and industry forecasts suggest that the contained inflation, growth-constructive scenario is more likely to play out. The Benefits for OXLC…

Read More

Yuwell Medical Partners with Inogen to Revolutionize Respiratory Health in Arab Health 2025

ilikefinance05 mins

DUBAI, UAE, Jan. 26, 2025 /PRNewswire/ — Yuwell Medical Announces Strategic Investment and Partnership with Inogen On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment…

Read More

NN Inc.: The Ultimate Tariff Beneficiary and Poster Child

newsit04 mins

New CEO Harold Bevis drives successful turnaround at NN Prossionally, educated, profit-focused, and intense Harold Bevis, a seasoned executive with significant turnaround experience, has taken the helm at NN and wasted no time in implementing drastic changes to revitalize the struggling company. Under his leadership, cost-cutting measures have been put into place, margins have been…

Read More

Mastercard Earnings Preview: Expect a Strong Q4, But Keep an Eye on Valuation Concerns

newsmaker04 mins

Mastercard’s Q4 Revenue Growth Expected to Remain Strong Overview Mastercard is expected to report solid Q4 revenue growth of 13-14%, driven by strong cross-border volumes and resilient e-commerce, despite FX headwinds. Profitability may contract due to rising operating expenses, particularly in Rebates & Incentives, which could weigh on margins amid competitive pressures. FY25 guidance appears…

Read More

“Attention Block Investors: Don’t Miss Out on this Class Action Reminder from Levi and Korsinsky!”

marketnews04 mins

Charmingly Eccentric: Embracing a Unique Personal Style The Intersection of Fashion and Personality There is something truly captivating about those who possess a charmingly eccentric personality. They exude a sense of individuality and creativity that is hard to ignore. It’s as if they have unlocked the secret to living life authentically and unapologetically. And when…

Read More

“FDA Gives Thumbs Up for IV Maintenance Dosing of Leqembi (Lecanemab-Irmb) to Combat Early Alzheimer’s Disease in the US!”

marketnews05 mins

Welcome to the Future of Alzheimer’s Treatment! Exciting News from BioArctic AB (publ) and Eisai STOCKHOLM, Jan. 26, 2025 /PRNewswire/ — BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic’s partner Eisai’s Supplemental Biologics License Application (sBLA) for Leqembi as a once every four…

Read More